Merus NV (NASDAQ:MRUS) – Stock analysts at Jefferies Financial Group lowered their FY2019 earnings per share estimates for Merus in a research note issued to investors on Wednesday, November 13th. Jefferies Financial Group analyst M. Raycroft now expects that the biotechnology company will earn ($1.72) per share for the year, down from their prior forecast of ($1.69). Jefferies Financial Group also issued estimates for Merus’ Q4 2019 earnings at ($0.45) EPS, FY2020 earnings at ($0.81) EPS, FY2021 earnings at ($1.81) EPS, FY2022 earnings at ($1.35) EPS and FY2023 earnings at $1.66 EPS.
MRUS has been the topic of several other reports. Zacks Investment Research upgraded shares of Merus from a “sell” rating to a “hold” rating in a research report on Tuesday, November 12th. BidaskClub upgraded shares of Merus from a “hold” rating to a “buy” rating in a research report on Thursday, September 26th. Finally, ValuEngine lowered shares of Merus from a “hold” rating to a “sell” rating in a research report on Friday, November 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $23.43.
Merus (NASDAQ:MRUS) last posted its quarterly earnings results on Monday, August 19th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.03). Merus had a negative return on equity of 40.56% and a negative net margin of 90.21%. The company had revenue of $6.27 million during the quarter, compared to analyst estimates of $8.62 million.
Large investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC bought a new position in shares of Merus in the third quarter valued at about $48,000. Morgan Stanley boosted its position in shares of Merus by 3.1% during the second quarter. Morgan Stanley now owns 92,776 shares of the biotechnology company’s stock worth $1,359,000 after buying an additional 2,788 shares during the period. Athanor Capital LP purchased a new position in shares of Merus during the second quarter worth $334,000. Artal Group S.A. boosted its position in shares of Merus by 16.7% during the second quarter. Artal Group S.A. now owns 350,000 shares of the biotechnology company’s stock worth $5,128,000 after buying an additional 50,000 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of Merus by 63.5% during the second quarter. JPMorgan Chase & Co. now owns 8,722 shares of the biotechnology company’s stock worth $123,000 after buying an additional 3,389 shares during the period. Hedge funds and other institutional investors own 50.56% of the company’s stock.
Merus Company Profile
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
Featured Article: What causes a yield curve to invert?
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.